U.S. IPO Weekly Recap: IPO Calendar Heats Up As AI Chipmaker Cerebras Rejoins The Public Pipeline

The important signal is not the headline IPO volume, but the reopening of the private-to-public valuation bridge after a long freeze. That tends to benefit late-stage venture holders first, but the second-order winner is the underwriting and market-making complex: more deals create a self-reinforcing feedback loop where successful clears pull forward additional filings, especially in high-growth sectors that have been starved of exit liquidity.

For hardware-heavy AI names, the bar is higher than for software: investors will likely use recent listings to demand cleaner unit economics, not just top-line growth. That creates a near-term dispersion trade—companies with obvious capital intensity and customer concentration may re-rate lower on debut, while asset-light AI enablers and picks-and-shovels infrastructure can still price well because they offer exposure without the same burn-rate overhang.

The biotech angle is trickier: large IPOs in healthcare often mark a local top in risk appetite because the market is willing to finance duration again before it is willing to underwrite binary clinical risk. If the calendar stays full for 2-4 weeks, the real risk is not failed deals but mediocre aftermarket performance, which can quickly cool the whole pipeline and hit VC marks, SPAC sentiment, and secondary issuance windows.

Consensus is probably overestimating how broad this reopening is. A few billion-dollar IPOs do not mean the market is ready to absorb every unicorn at premium multiples; it usually means only the highest-quality, most narrative-friendly names get through first, while weaker companies are forced to accept lower valuation or delay. In other words, this is bullish for select deal quality, but not necessarily bullish for the average late-stage private asset.